Business Combination, Aggregate Upfront Payments

No definition available.

Name:	cpix_BusinessCombinationAggregateUpfrontPayments
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Business Combination, Royalties, Range of Payment Over Gross Profits, Percentage

+ References

No definition available.

+ Details

Name:	cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage
Namespace Prefix:	cpix_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Business Combination, Upfront Payment

+ References

No definition available.

+ Details

Name:	cpix_BusinessCombinationUpfrontPayment
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Payments for Contingent Consideration

+ References

No definition available.

+ Details

Name:	cpix_PaymentsforContingentConsideration
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Product RIghts Agreement, Milestone Payment

+ References

No definition available.

+ Details

Name:	cpix_ProductRIghtsAgreementMilestonePayment
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Recognized Gain (Loss) on Contingent Consideration

+ References

No definition available.

+ Details

Name:	cpix_RecognizedGainLossonContingentConsideration
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue Recognition, Potential Upfront Payment Related to Product Sales

+ References

No definition available.

+ Details

Name:	cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_SalesRevenueNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=cpix_OmeclamoxPakMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=cpix_VaprisolMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cpix_AmendedInternationalAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=cpix_PernixTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=cpix_OmeclamoxPakMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=cpix_VaprisolMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Products Added During 2014 and 2013 - Narrative (Details) - USD ($)		1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Oct. 29, 2013	Apr. 30, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Feb. 28, 2014
Business Acquisition [Line Items]
Payments for contingent considerations					$ 1,618,983	$ 0
Net revenues			$ 8,909,741	$ 9,750,168	17,596,515	17,843,412
Upfront payments and milestone payments related to product sales					4,000,000
Omeclamox-Pak
Business Acquisition [Line Items]
Additional upfront payments	$ 4,000,000
Milestone payment							$ 1,000,000
Vaprisol
Business Acquisition [Line Items]
Upfront payment								$ 2,000,000
Additional upfront payments								$ 2,000,000
Payments for contingent considerations		$ 1,600,000
Recognized gain on contingent consideration					300,000
Minimum \| Omeclamox-Pak
Business Acquisition [Line Items]
Royalty payments based on percentage over gross profits	15.00%
Maximum \| Omeclamox-Pak
Business Acquisition [Line Items]
Royalty payments based on percentage over gross profits	20.00%
Amended International Agreement \| Pernix Therapeutics
Business Acquisition [Line Items]
Upfront payments and milestone payments related to product sales	$ 4,000,000
Omeclamox-Pak
Business Acquisition [Line Items]
Net revenues			900,000	1,300,000	1,700,000	2,500,000
Vaprisol
Business Acquisition [Line Items]
Net revenues			$ 500,000	$ 1,100,000	$ 1,500,000	$ 1,400,000